US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Polyrizon Ltd.

0.0089

-0.0037-29.37%

Post-market: 0.0088-0.0001-1.12%18:41 EDT

Volume:425.79M

Turnover:4.35M

Market Cap:60.57K

PE:- -

High:0.0111

Open:0.0111

Low:0.0085

Close:0.0126

Loading ...

Overview Company News Filings

BRIEF-Polyrizon Ltd Files Prospectus Related To Resale By Selling Shareholders Of Up To 2.4 Million Ordinary Shares - SEC Filing

Polyrizon files to sell 2.42M ordinary shares for holders

Polyrizon Ltd: Files Prospectus Related to Resale by Selling Shareholders of up to 2.4 Mln Ordinary Shares - SEC Filing

THOMSON REUTERS

Polyrizon Shares Rise After Publication of National Patent Application

Risk Aversion Grips Wall Street in Penultimate Session of 2024, Fueling Premarket Losses for US Equity Futures

MT Newswires Live

Polyrizon Files US Patent Application for Nasal Drug Delivery Platforms; Shares Jump Pre-Bell

MT Newswires Live

Top Premarket Gainers

MT Newswires Live

Polyrizon announces publication of patent application for hydrogel nasal tech

Polyrizon appoints Michal Meir as senior director, regulatory & clinical affairs

Polyrizon Appoints DR. Michal Meir as Senior Director of Regulatory and Clinical Affairs

THOMSON REUTERS

Press Release: Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

Polyrizon Shares Surge on Impending Clinical Trial

Polyrizon Collaborating With Eurofins CDMO for Clinical Trial of Allergy Blocker; Shares Jump

MT Newswires Live

Polyrizon's Moving Forward With Expected 2025 Clinical Trial - Entered Manufacturing Agreement for Its Pl-14 Allergy Blocker

THOMSON REUTERS

Polyrizon Announces Appointment of Vp of Regulatory Affairs and Quality Assurance

THOMSON REUTERS

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

Polyrizon Enters Into Gmp Manufacturing Agreement for Ctm Supply of Its Pl-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PLRZ/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PLRZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","market":"US","secType":"STK","nameCN":"Polyrizon Ltd.","latestPrice":0.0089,"timestamp":1747339200000,"preClose":0.0126,"halted":0,"volume":425787281,"hourTrading":{"tag":"盘后","latestPrice":0.0088,"preClose":0.0089,"latestTime":"18:41 EDT","volume":7579251,"amount":65523.761782650006,"timestamp":1747348865330},"delay":0,"floatShares":4724727,"shares":6805210,"eps":0,"marketStatus":"Post-Mkt","change":-0.0037,"latestTime":"05-15 18:41:11 EDT","open":0.0111,"high":0.0111,"low":0.0085,"amount":4347268.127007794,"amplitude":0.206349,"askPrice":0.0089,"askSize":1000,"bidPrice":0.0085,"bidSize":101,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1747353600000},"marketStatusCode":4,"adr":0,"listingDate":1730174400000,"exchange":"NASDAQ","adjPreClose":0.0126,"preHourTrading":{"tag":"盘前","latestPrice":0.0109,"preClose":0.0126,"latestTime":"09:29 EDT","volume":35052402,"amount":422552.569926564,"timestamp":1747315799751},"postHourTrading":{"tag":"盘后","latestPrice":0.0088,"preClose":0.0089,"latestTime":"18:41 EDT","volume":7579251,"amount":65523.761782650006,"timestamp":1747348865330},"volumeRatio":2.835},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","floatShares":4724727,"roa":"-26.65%","roe":"-57.83%","lyrEps":0,"volumeRatio":2.835,"shares":6805210,"dividePrice":0,"high":0.0111,"amplitude":0.206349,"preClose":0.0126,"low":0.0085,"week52Low":0.0085,"pbRate":"0.01","week52High":4.8,"institutionHeld":0,"latestPrice":0.0089,"committee":-0.81653,"eps":0,"divideRate":0,"volume":425787281,"delay":0,"ttmEps":0,"open":0.0111,"prevYearClose":2.17,"prevWeekClose":0.3747,"prevMonthClose":0.31,"prevQuarterClose":0.369,"fiveDayClose":0.5908,"twentyDayClose":0.363,"sixtyDayClose":1.08},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PLRZ\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2495509835","title":"BRIEF-Polyrizon Ltd  Files Prospectus Related To Resale By Selling Shareholders Of Up To 2.4 Million Ordinary Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2495509835","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495509835?lang=en_us&edition=fundamental","pubTime":"2024-12-31 06:02","pubTimestamp":1735596121,"startTime":"0","endTime":"0","summary":"BRIEF-Polyrizon Ltd  Files Prospectus Related To Resale By Selling Shareholders Of Up To 2.4 Million Ordinary Shares - SEC FilingDec 30  - Polyrizon Ltd PLRZ.O:POLYRIZON LTD:  FILES PROSPECTUS RELATED TO RESALE BY SELLING SHAREHOLDERS OF UP TO 2.4 MILLION ORDINARY SHARES - SEC FILINGSource text: [ID:n0001213900-24-113515]Further company coverage: PLRZ.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241230:nFWN3NV0C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2495509102","title":"Polyrizon files to sell 2.42M ordinary shares for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2495509102","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495509102?lang=en_us&edition=fundamental","pubTime":"2024-12-31 06:00","pubTimestamp":1735596010,"startTime":"0","endTime":"0","summary":"16:56 EST Polyrizon (PLRZ) files to sell 2.42M ordinary shares for holders Published first on TheFly – the ultimate source for real-time, market-mo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-files-to-sell-2-42m-ordinary-shares-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-files-to-sell-2-42m-ordinary-shares-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ"],"gpt_icon":0},{"id":"2495054506","title":"Polyrizon Ltd:  Files Prospectus Related to Resale by Selling Shareholders of up to 2.4 Mln Ordinary Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2495054506","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495054506?lang=en_us&edition=fundamental","pubTime":"2024-12-31 05:59","pubTimestamp":1735595976,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241230:nFWN3NV0C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2495521153","title":"Polyrizon Shares Rise After Publication of National Patent Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2495521153","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495521153?lang=en_us&edition=fundamental","pubTime":"2024-12-30 23:34","pubTimestamp":1735572840,"startTime":"0","endTime":"0","summary":"Shares of Polyrizon were up 34% to $2.19 after the company said the U.S. Patent and Trademark Office published a national phase patent application by the company.Shares of the Israel-based company, which launched its initial public offering in October, traded as high as $4.80 on Dec. 18.The biotechnology company said the patent application is for two core platform technologies: Capture and Contain, a nasal blocker technology, and Trap and Target, designed for advanced nasal drug delivery.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","NHLD"],"gpt_icon":0},{"id":"2495470035","title":"Risk Aversion Grips Wall Street in Penultimate Session of 2024, Fueling Premarket Losses for US Equity Futures","url":"https://stock-news.laohu8.com/highlight/detail?id=2495470035","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495470035?lang=en_us&edition=fundamental","pubTime":"2024-12-30 22:00","pubTimestamp":1735567203,"startTime":"0","endTime":"0","summary":"US equity futures dropped ahead of Monday's opening bell as traders turned risk-averse in the penultimate trading session of 2024.The Dow Jones Industrial Average futures slipped 1%, S&P 500 futures d","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UDOW","DXD","TQQQ","BK4585","SDOW","BK4007","QID","PLRZ","QLD","DOG","USAW.SI","TSYW.SI","PSQ",".IXIC","BK4215",".DJI","BK4588","SQQQ","MNQmain","DJX","USJW.SI","NQmain",".SPX","TRAW","EQR","NVIW.SI","DDM"],"gpt_icon":1},{"id":"2495849542","title":"Polyrizon Files US Patent Application for Nasal Drug Delivery Platforms; Shares Jump Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2495849542","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495849542?lang=en_us&edition=fundamental","pubTime":"2024-12-30 21:25","pubTimestamp":1735565123,"startTime":"0","endTime":"0","summary":"Polyrizon  announced Monday the publication of its national phase patent application with the US Patent and Trademark Office.The application covers its core nasal technologies: capture and contain, a blocker system, and trap and target, designed for advanced drug delivery.US patent applications are generally published after 18 months from the date of filing.Shares of the company jumped more than 60% in recent premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PLRZ"],"gpt_icon":0},{"id":"2495254983","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2495254983","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495254983?lang=en_us&edition=fundamental","pubTime":"2024-12-30 20:38","pubTimestamp":1735562291,"startTime":"0","endTime":"0","summary":"Eightco Holdings  shares more than doubled pre-bell Monday following a 3.2% increase in the previous session.Intrusion  shares soared 93% after increasing nearly five-fold on Friday.Polyrizon  shares were up 74% after the company announced a publication by the US Patent States Patent and Trademark Office of a patent application covering hydrogel nasal technologies.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["INTZ","BK4136","PLRZ","BK4097","OCTO"],"gpt_icon":0},{"id":"2495543596","title":"Polyrizon announces publication of patent application for hydrogel nasal tech","url":"https://stock-news.laohu8.com/highlight/detail?id=2495543596","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495543596?lang=en_us&edition=fundamental","pubTime":"2024-12-30 19:35","pubTimestamp":1735558530,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) announced the publication of a national phase patent application by the United States Patent and Trademark Office. The patent appl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-announces-publication-of-patent-application-for-hydrogel-nasal-tech?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-announces-publication-of-patent-application-for-hydrogel-nasal-tech?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ"],"gpt_icon":0},{"id":"2492244651","title":"Polyrizon appoints Michal Meir as senior director, regulatory & clinical affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2492244651","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492244651?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:30","pubTimestamp":1734611443,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) announced the appointment of Dr. Michal Meir, Senior Consultant at MedTech, as Senior Director of Regulatory and Clinical Affairs....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-appoints-michal-meir-as-senior-director-regulatory-clinical-affairs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-appoints-michal-meir-as-senior-director-regulatory-clinical-affairs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ"],"gpt_icon":0},{"id":"2492412104","title":"Polyrizon Appoints DR. Michal Meir as Senior Director of Regulatory and Clinical Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2492412104","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492412104?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:22","pubTimestamp":1734610920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUABPZKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2492912107","title":"Press Release: Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2492912107","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492912107?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:22","pubTimestamp":1734610920,"startTime":"0","endTime":"0","summary":"Raanana, Israel, Dec. 19, 2024  -- Polyrizon Ltd.  , a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of Dr. Michal Meir, Senior Consultant at MedTech SME Ltd., as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of the Company's preparations towards its clinical trial for PL-14 that is expected to commence in 2025. Dr. Meir brings over a decade of experience in the medical device and pharmaceutical industries, with a proven track record in regulatory strategy, clinical affairs management and product development.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","03160","TM","BK4099","PLRZ","BK4555","BK4588"],"gpt_icon":1},{"id":"2492913875","title":"Polyrizon Shares Surge on Impending Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2492913875","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492913875?lang=en_us&edition=fundamental","pubTime":"2024-12-19 00:02","pubTimestamp":1734537720,"startTime":"0","endTime":"0","summary":"Shares of Polyrizon more than quadrupled intraday after the biotech company said it is moving forward with an allergy blocker clinical trial next year.The stock on Wednesday gained as much as 357% to $4.80, a new 52-week high, and was halted soon after the open for volatility. More recently it was up 216% to $3.32.The Israel-based biotech company said it has entered a manufacturing agreement for its PL-14 allergy blocker with Eurofins CDMO Amatsiaquitaine S.A.S., an EU-based GMP manufacturing facility. The collaboration will support its upcoming clinical trial for the nasal spray treatment, expected to start next year, Polyrizon said.The company added that the manufacturing site is set to support the trial, offering development programs in line with U.S. and European regulatory standards.Polyrizon previously announced the upcoming trial and manufacturing agreement earlier this month.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":1},{"id":"2492183749","title":"Polyrizon Collaborating With Eurofins CDMO for Clinical Trial of Allergy Blocker; Shares Jump","url":"https://stock-news.laohu8.com/highlight/detail?id=2492183749","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492183749?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:22","pubTimestamp":1734528159,"startTime":"0","endTime":"0","summary":"Polyrizon  said Wednesday it has entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine, a European-based GMP-certified manufacturer, to supply clinical trial material for its PL-14 allergy blocker study expected to begin in 2025.The trial aims to evaluate the safety and efficacy of PL-14 as an allergy blocker, the company said.Polyrizon said the manufacturing site for the clinical trial material will meet US and European regulatory standards and provide high-quality development support for the 2025 trial.Polyrizon shares were 160% higher in premarket trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CDMO","PLRZ"],"gpt_icon":1},{"id":"2492011009","title":"Polyrizon's Moving Forward With Expected 2025 Clinical Trial - Entered Manufacturing Agreement for Its Pl-14 Allergy Blocker","url":"https://stock-news.laohu8.com/highlight/detail?id=2492011009","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492011009?lang=en_us&edition=fundamental","pubTime":"2024-12-18 19:25","pubTimestamp":1734521100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUAC1R5G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2491325955","title":"Polyrizon Announces Appointment of Vp of Regulatory Affairs and Quality Assurance","url":"https://stock-news.laohu8.com/highlight/detail?id=2491325955","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491325955?lang=en_us&edition=fundamental","pubTime":"2024-12-13 19:25","pubTimestamp":1734089100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nTUA4GVMLQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2491325432","title":"Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance","url":"https://stock-news.laohu8.com/highlight/detail?id=2491325432","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491325432?lang=en_us&edition=fundamental","pubTime":"2024-12-13 19:25","pubTimestamp":1734089100,"startTime":"0","endTime":"0","summary":"Raanana, Israel, Dec. 13, 2024  -- Polyrizon Ltd.  , a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins’ Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance . This strategic appointment reflects Polyrizon’s ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions.Asaf Azulay brings over 20 years of extensive experience in the medical devices industry, with expertise in leading quality teams and implementing regulatory strategies. His deep understanding of the global regulatory landscape will play a vital role in ensuring Polyrizon’s compliance with international standards and achieving its strategic goals.\"We are excited to strengthen our team with proven expertise in RA/QA to support Polyrizon’s mission of delivering safe and effective solutions to market,” s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polyrizon-announces-appointment-vp-regulatory-112500190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PLRZ"],"gpt_icon":0},{"id":"2488568676","title":"Polyrizon Enters Into Gmp Manufacturing Agreement for Ctm Supply of Its Pl-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2488568676","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488568676?lang=en_us&edition=fundamental","pubTime":"2024-12-02 21:02","pubTimestamp":1733144520,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nTUA8B0TTC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":57,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLRZ\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLRZ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLRZ\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLRZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLRZ","date":"2025-05-14","current":-0.125533,"percent":1,"low":-29.515607,"twenty":-5.050826,"median":-3.37037,"eighty":-1.421061,"high":-0.125533,"avg":-3.784384,"sd":3.116248,"marketCap":193948},"quantilePoints":[{"date":"2024-10-31","current":-13.097935,"twenty":-22.948538,"median":-13.097935,"eighty":-12.489816,"marketCap":7858761},{"date":"2024-11-08","current":-3.903419,"twenty":-12.692522,"median":-4.690878,"eighty":-4.316449,"marketCap":3891709},{"date":"2024-11-15","current":-2.661127,"twenty":-9.219549,"median":-4.249136,"eighty":-3.530862,"marketCap":2653144},{"date":"2024-11-22","current":-2.985655,"twenty":-4.737156,"median":-3.736612,"eighty":-3.09924,"marketCap":2976698},{"date":"2024-11-29","current":-3.042447,"twenty":-4.451075,"median":-3.375089,"eighty":-3.037515,"marketCap":3033320},{"date":"2024-12-06","current":-3.212824,"twenty":-4.383762,"median":-3.342636,"eighty":-3.042447,"marketCap":3203186},{"date":"2024-12-13","current":-3.375088,"twenty":-4.191157,"median":-3.358862,"eighty":-3.047315,"marketCap":3364963},{"date":"2024-12-20","current":-7.561496,"twenty":-4.383762,"median":-3.375088,"eighty":-3.07146,"marketCap":7538812},{"date":"2024-12-27","current":-5.744141,"twenty":-5.095085,"median":-3.407542,"eighty":-3.090153,"marketCap":5726909},{"date":"2025-01-03","current":-5.938858,"twenty":-6.101122,"median":-3.569805,"eighty":-3.132991,"marketCap":5921041},{"date":"2025-01-10","current":-4.997727,"twenty":-6.159537,"median":-3.796975,"eighty":-3.146231,"marketCap":4982734},{"date":"2025-01-17","current":-6.142316,"twenty":-6.098128,"median":-3.933764,"eighty":-3.167391,"marketCap":6123889},{"date":"2025-01-24","current":-5.889893,"twenty":-6.192801,"median":-4.333277,"eighty":-3.193353,"marketCap":5872223},{"date":"2025-01-31","current":-5.553327,"twenty":-6.125488,"median":-4.527162,"eighty":-3.214122,"marketCap":5536667},{"date":"2025-02-07","current":-4.552045,"twenty":-6.087615,"median":-4.738105,"eighty":-3.227753,"marketCap":4538389},{"date":"2025-02-14","current":-4.711914,"twenty":-6.064471,"median":-4.705652,"eighty":-3.245278,"marketCap":4697778},{"date":"2025-02-21","current":-4.522596,"twenty":-6.049761,"median":-4.627772,"eighty":-3.258259,"marketCap":4509028},{"date":"2025-02-28","current":-3.707687,"twenty":-6.000655,"median":-4.535397,"eighty":-3.316674,"marketCap":3696564},{"date":"2025-03-07","current":-3.460732,"twenty":-5.929065,"median":-4.501561,"eighty":-3.241954,"marketCap":3450350},{"date":"2025-03-14","current":-1.846098,"twenty":-5.873065,"median":-4.396383,"eighty":-3.213473,"marketCap":2852222},{"date":"2025-03-21","current":-1.508371,"twenty":-5.793429,"median":-4.291207,"eighty":-3.160314,"marketCap":2330433},{"date":"2025-03-28","current":-1.353625,"twenty":-5.705978,"median":-3.977976,"eighty":-3.07146,"marketCap":2091350},{"date":"2025-04-04","current":-0.974631,"twenty":-5.536499,"median":-3.903419,"eighty":-3.030526,"marketCap":1505805},{"date":"2025-04-11","current":-0.980061,"twenty":-5.4398,"median":-3.702849,"eighty":-2.640357,"marketCap":1514194},{"date":"2025-04-17","current":-0.985491,"twenty":-5.322255,"median":-3.619184,"eighty":-1.846098,"marketCap":1522583},{"date":"2025-04-25","current":-0.947483,"twenty":-5.174691,"median":-3.5049,"eighty":-1.520317,"marketCap":1463861},{"date":"2025-05-02","current":-0.687943,"twenty":-5.159991,"median":-3.434137,"eighty":-1.353625,"marketCap":1062872},{"date":"2025-05-09","current":-2.602277,"twenty":-5.095085,"median":-3.375088,"eighty":-1.466019,"marketCap":4020518},{"date":"2025-05-14","current":-0.125533,"twenty":-5.050826,"median":-3.37037,"eighty":-1.421061,"marketCap":193948}],"updateTime":1747314625722}}}